

# Ocular Hypertension

[View the current Ocular Hypertension InDepth page on BioPortfolio.com \(PDF\)](#)  
([http://www.bioportfolio.com/indepth/Ocular\\_Hypertension.html](http://www.bioportfolio.com/indepth/Ocular_Hypertension.html)) - Regularly Updated.



## Recent Publications on Ocular Hypertension:

- [The effects of combination glaucoma medications on ocular surface epithelial cells.](#)  
*INTRODUCTION: The purpose of this study was to determine the effects of...*19th November, 2009  
Rocky Mountain Lions Eye Institute, Department of Ophthalmology,- Adv Ther. 2009 Nov 18. ([DOI Direct Link](#))
- [Diffuse glaucomatous structural and functional damage in the hemifield without significant pattern loss.](#)  
*OBJECTIVES: To compare the retinal nerve fiber layer (RNFL) thickness and...*18th November, 2009  
Palmer Eye Institute, Department of Ophthalmology, University of Miami- Arch Ophthalmol. 2009 Nov;127(11):1442-8. ([DOI Direct Link](#))
- [Healthcare charges in patients who transition from ocular hypertension to primary open-angle glaucoma based on ophthalmic coding data.](#)  
*INTRODUCTION: The purpose of this research was to assess the impact of...*13th November, 2009  
Glaucoma Service, Massachusetts Eye and Ear Infirmary, Harvard Medical- Adv Ther. 2009 Nov 11. ([DOI Direct Link](#))
- [\[Complications of uveitis: prevalence and risk factors in a serie of 398 cases.\]](#)  
*OBJECTIVE: To estimate the rate of complications and establish risk...*11th November, 2009  
Hospital de La Princesa, Servicio de Oftalmologia, Madrid, Espana.- Arch Soc Esp Oftalmol. 2009 Oct;84(10):523-8.
- [A randomized, 36-month, post-marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-prostaglandin therapy in patients with glaucoma or ocular hypertension.](#)  
*Abstract. Purpose: To compare the effect of time on therapy, efficacy,...*11th November, 2009  
University Hospital, Linkoping, Sweden.- Acta Ophthalmol. 2009 Nov 7. ([DOI Direct Link](#))
- [\[Steroid induced ocular hypertension and glaucoma\]](#)  
*Steroid induced ocular hypertension and glaucoma represent iatrogenic...*11th November, 2009  
- Oftalmologia. 2009;53(3):15-33.
- [Role of fixed-combination brinzolamide 1%/timolol 0.5% in the treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension.](#)  
*Brinzolamide 1%/timolol 0.5% is a new fixed-combination for the treatment...*10th November, 2009  
University Eye Clinic, Maastricht, The Netherlands.- Clin Ophthalmol. 2009;3:593-9. Epub 2009 Nov 2.
- [Astrocyte and microglial activation in the lateral geniculate nucleus and visual cortex of glaucomatous and optic nerve transected primates.](#)  
*PURPOSE: To examine early cellular changes, including astrocyte reactivity...*10th November, 2009  
Southern California College of Optometry, Fullerton, CA, USA.- Mol Vis. 2009 Oct 31;15:2217-29.
- [The Ability of Short-Wavelength Automated Perimetry to Predict Conversion to Glaucoma.](#)

*PURPOSE: Short-wavelength automated perimetry (SWAP) has been claimed to...*10th November, 2009

Glaucoma Service, The Rotterdam Eye Hospital, Rotterdam, The Netherlands.- Ophthalmology. 2009 Nov 5. ([DOI Direct Link](#))

- [Risk of glaucoma in elderly patients treated with inhaled corticosteroids for chronic airflow obstruction.](#)

*BACKGROUND: Topical and systemic corticosteroids are well known to raise...*6th November, 2009  
Respiratory Epidemiology and Clinical Research Unit, Montreal Chest- Pulm Pharmacol Ther. 2009 Nov 1. ([DOI Direct Link](#))

- [Xal-Ease\(R\): impact of an ocular hypotensive delivery device on ease of eyedrop administration, patient compliance, and satisfaction.](#)

*Purpose. To measure the impact of the Xal-Ease(R) delivery device on ease...*3rd November, 2009  
- Eur J Ophthalmol. 2009 Nov-Dec;19(6):949-56.

- [Intraocular pressure reduction after phacoemulsification with intraocular lens implantation in glaucomatous and nonglaucomatous eyes: evaluation of a causal relationship between the natural lens and open-angle glaucoma.](#)

*PURPOSE: To study the long-term effects of phacoemulsification with...*3rd November, 2009  
Volunteers in Medicine, Hilton Head Island, South Carolina 29910, USA.- J Cataract Refract Surg. 2009 Nov;35(11):1946-55. ([DOI Direct Link](#))

- [A Comparison of Optic Nerve Head Morphology Viewed by Spectral Domain Optical Coherence Tomography and By Serial Histology.](#)

*PURPOSE: To compare serial optic nerve head (ONH) histology with...*31st October, 2009  
Optic Nerve Head Research Laboratory, Devers Eye Institute, Portland,- Invest Ophthalmol Vis Sci. 2009 Oct 29. ([DOI Direct Link](#))

- [Evaluation of Sub-Tenon Triamcinolone Acetonide Injections in the Treatment of Scleritis.](#)

*PURPOSE: To suggest that sub-Tenon triamcinolone acetonide (TA) injections...*31st October, 2009  
Department of Ophthalmology, New Jersey Medical School-University of- Am J Ophthalmol. 2009 Oct 27. ([DOI Direct Link](#))

## Ocular Hypertension Patents:



- 7517912- [Prostaglandin analog compositions and methods to treat epithelial-related conditions](#)
- 7550448- [Therapeutic compounds](#)
- 7550462- [Piperazinediones as oxytocin receptor antagonists](#)
- 7550502- [Substituted gamma lactams as therapeutic agents](#)
- 7550508- [Prostaglandin analog compositions and methods to treat epithelial-related conditions](#)
- 7551293- [Method and apparatus for three-dimensional spectrally encoded imaging](#)
- 7553860- [Substituted gamma lactams as therapeutic agents](#)
- 7553874- [Prostaglandin analog compositions and methods to treat epithelial-related conditions](#)
- 7553875- [Prostaglandin analog compositions and methods to treat epithelial-related conditions](#)
- 7556380- [Apparatus and method for self-measurement of intraocular pressure](#)
- 7557095- [Therapeutic compounds](#)
- 7547727- [Therapeutic cyclopentane derivatives](#)
- 7547720- [Ophthalmic compositions for treating ocular hypertension](#)
- 7547685- [Therapeutic substituted pyrrolidone compounds](#)

- [7519096- Process and apparatus for a wavelength tuning source](#)
- [7521449- 4-arylmorpholin-3-one derivatives, their preparation and therapeutic use thereof](#)
- [7524064- Apparatus and method for assessing retinal damage](#)
- [7524886- L-\(-\)-moprolol L-\(+\)-tartrate](#)
- [7528163- Ophthalmic compositions for treating ocular hypertension](#)
- [7528282- Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme](#)
- [7534795- Compounds and their use related to compositions for treating disease](#)
- [7538859- Methods and systems for monitoring and obtaining information of at least one portion of a sample using conformal laser therapy procedures, and providing electromagnetic radiation thereto](#)
- [7541382- Prostaglandin analog compositions and methods to treat epithelial-related conditions](#)
- [7544814- \[3.2.0\] Heterocyclic compounds and methods of using the same](#)
- [7557196- hGC-1, a gene encoding a member of the olfactomedin-related protein family](#)
- [7560100- Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases](#)
- [7589057- Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems](#)
- [7592324- RNAi-mediated inhibition of ocular targets](#)
- [7592330- Methods and compositions for preserving the viability of photoreceptor cells](#)
- [7592364- Substituted gamma lactams as therapeutic agents](#)
- [7592366- Therapeutic compounds](#)
- [7598288- Inhibitors of glycogen synthase kinase-3 \(GSK-3\) for treating glaucoma](#)
- [7605178- Therapeutic compounds](#)
- [7612047- Degradation-resistant mononucleoside phosphate compounds](#)
- [7612101- Abnormal cannabidiols as agents for lowering intraocular pressure](#)
- [7618966- Abnormal Cannabidiols as agents for lowering intraocular pressure](#)
- [7585895- Therapeutic substituted cyclopentanes](#)
- [7585889- Internal 1,15-lactones of fluprostenol and related prostaglandin F.sub.2.alpha. analogs and their use in the treatment of glaucoma and intraocular hypertension](#)
- [7585877- Aminophenyl derivatives as selective androgen receptor modulators](#)
- [7560448- Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application](#)
- [7563816- Ophthalmic compositions for treating ocular hypertension](#)
- [7563906- Indazole derivatives](#)
- [7566725- Imidazo\[1,2-A\] pyridine anxiolytics](#)
- [7567349- Speckle reduction in optical coherence tomography by path length encoded angular compounding](#)
- [7572920- Benzimidazole derivative and use as a II receptor antagonist](#)
- [7576112- Therapeutic N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives](#)
- [7576122- Ophthalmic compositions for treating ocular hypertension](#)
- [7579371- Methods of using \[3.2.0\] heterocyclic compounds and analogs thereof](#)
- [7582662- Body weight gain inhibitor](#)
- [7618984- Sulfonamide compound](#)

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road,  
Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

